Prostate Cancer
Conference Coverage
Colorectal cancer treatment outcomes in older adults
Disease-free survival boosted by adjuvant therapy completion, but only about half of patients finish.
Feature
New cancer data spark outcry from patient advocates
The American Cancer Society on Jan. 13 revealed what it called ‘alarming’ news about prostate cancer.
From the Journals
‘Low-value’ prostate cancer screening prevalent in primary care
A new study shows that testing for prostate-specific antigen and also digital rectal examinations are both carried out frequently in older men.
Conference Coverage
Most men with low-risk prostate tumors now forgoing treatment
Roughly 60% of men eligible for active surveillance chose that approach in 2021, up from 27% in 2014 and less than 10% in 2010.
From the Journals
Is it time to remove ‘cancer’ label from low-risk prostate tumors?
Experts argue that overtreatment could be reduced by removing the word “cancer” from low-risk disease.
Latest News
MRI far safer than CT for guiding radiotherapy in prostate cancer
MRI guidance more than halved the risk of genitourinary toxicities.
From the Journals
Urine test for prostate cancer signals amount of aggressive tumor
“PUR will also be useful for monitoring disease in men that do not currently require treatment and flag up the emergence” of aggressive disease....
Latest News
Old saying about prostate cancer not true when it’s metastatic
“Most patients with metastatic prostate cancer die from it, rather than other possible causes of death,” researcher says.
Conference Coverage
Healthy lifestyle may offset genetic risk in prostate cancer
In men at the highest risk of dying from prostate cancer, a healthy lifestyle cut the risk of fatal disease in half.
Conference Coverage
CCR score can guide treatment decisions after radiation in prostate cancer
The score can identify patients with a low risk of metastasis who could potentially skip androgen deprivation therapy.
Conference Coverage
Declines in PSA screening may account for rise in metastatic prostate cancers
Longitudinal reductions in PSA screening across U.S. states were associated with increased incidence of metastatic prostate cancer.